Kevin McDonnell, PhD

Vice President, Chemistry US at Bicycle Therapeutics

Speaker

Dr. Kevin McDonnell obtained his undergraduate degree at the University of New Brunswick and subsequently his Ph.D. in Biology and Chemistry at the Massachusetts Institute of Technology (MIT). He began his professional career developing synthetic peptides targeting the neonatal Fc receptor (FcRn) and therapeutic recombinant Fc fusion proteins at Syntonix Pharmaceuticals and Biogen. He then headed up the discovery chemistry efforts at BIND Therapeutics and drove the discovery of small molecule, peptide and protein-conjugated polymeric nanoparticles for targeted delivery of anti-cancer agents. Currently, as Vice President of Chemistry for Bicycle Therapeutics, Dr. McDonnell is responsible for advancing bicyclic peptide therapeutics in the oncology discovery programs.